World's Best Scientists 2026 revealed!
Steven R. Alberts

Steven R. Alberts

D-Index & Metrics

Medicine

D-Index
87
Citations
31863
World Ranking
13538
National Ranking
6885

Steven R. Alberts publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Steven R. Alberts sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 411 publications — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Steven R. Alberts D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Steven R. Alberts sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Steven R. Alberts is affiliated with the Mayo Clinic in the United States. Their research primarily centers on medicine, with a focus on oncology, surgery, pathology and forensic medicine, pulmonary and respiratory medicine, and cancer research. The scientist's work spans multiple facets of colorectal, gastric, pancreatic, and hepatic cancers, highlighting both treatment approaches and diagnostic advances.

The main topics of their research include:

  • Colorectal Cancer Treatments and Studies
  • Genetic factors in colorectal cancer
  • Colorectal Cancer Surgical Treatments
  • Gastric Cancer Management and Outcomes
  • Pancreatic and Hepatic Oncology Research
  • Colorectal Cancer Screening and Detection
  • Cancer Genomics and Diagnostics

Frequent co-authors collaborate with Steven R. Alberts in various studies, including:

  • Qian Shi
  • Richard M. Goldberg
  • Frank A. Sinicrope
  • Julien Taïeb
  • Greg Yothers

The scientist has published extensively in several key venues, with the highest number of publications appearing in:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Journal of Cancer
  • UNC Libraries
  • Cancer Epidemiology Biomarkers & Prevention

Significant recent papers exemplify the focus and scope of their research, such as:

  • "Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200," 2023, Journal of Clinical Oncology
  • "Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials," 2020, Journal of Clinical Oncology
  • "A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer," 2023, Journal of Clinical Oncology
  • "Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34,640 Patients in the ACCENT Database," 2020, JNCI Journal of the National Cancer Institute
  • "Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance)," 2020, Annals of Oncology

Best Publications

  • Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

    Bruce J. Giantonio;Paul J. Catalano;Neal J. Meropol;Peter J. O'Dwyer

  • A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer

    Richard M. Goldberg;Daniel J. Sargent;Roscoe F. Morton;Charles S. Fuchs

  • Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

    Sharlene Gill;Charles L. Loprinzi;Daniel J. Sargent;Stephan D. Thomé

  • Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial

    Patrick J. Loehrer;Yang Feng;Higinia Cardenes;Lynne Wagner

  • Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates

    G. Folprecht;A. Grothey;S. Alberts;H.-R. Raab

  • Liver Transplantation with Neoadjuvant Chemoradiation is More Effective than Resection for Hilar Cholangiocarcinoma

    David J. Rea;Julie K. Heimbach;Charles B. Rosen;Michael G. Haddock

  • Oxaliplatin, Fluorouracil, and Leucovorin for Patients With Unresectable Liver-Only Metastases From Colorectal Cancer: A North Central Cancer Treatment Group Phase II Study

    Steven R. Alberts;William L. Horvath;William C. Sternfeld;Richard M. Goldberg

  • Gastric cancer: epidemiology, pathology and treatment

    S. R. Alberts;A. Cervantes;C. J. H. van de Velde

  • Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841

    Jan Franko;Qian Shi;Charles D. Goldman;Barbara A. Pockaj

  • Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group

    Elizabeth Poplin;Yang Feng;Jordan Berlin;Mace L. Rothenberg

  • Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.

    Steven R Alberts;Daniel J Sargent;Suresh G. Nair Md;Michelle R Mahoney

  • High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200

    B. J. Giantonio;P. J. Catalano;N. J. Meropol;P. J. O'Dwyer

  • Hepatitis B-related sequelae: prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers.

    Brian J. McMahon;Steven R. Alberts;Robert B. Wainwright;Lisa Bulkow

  • SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

    Edgar Ben-Josef;Katherine A. Guthrie;Anthony B. El-Khoueiry;Christopher L. Corless

  • Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.

    Frank A. Sinicrope;Qian Shi;Thomas C. Smyrk;Stephen N. Thibodeau

  • Hepatobiliary Cancers, Version 1.2017: Featured Updates to the NCCN Guidelines

    Al B. Benson;Michael I. D'Angelica;Daniel E. Abbott;Thomas A. Abrams

  • OncoSurge: A Strategy for Improving Resectability With Curative Intent in Metastatic Colorectal Cancer

    Graeme J. Poston;René Adam;Steven Alberts;Steven Curley

  • Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design

    Matthew Harold Katz;Robert Marsh;Joseph M. Herman;Qian Shi

  • Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy

    Frank A. Sinicrope;Michelle R. Mahoney;Thomas C. Smyrk;Stephen N. Thibodeau

  • Randomized Controlled Trial of Reduced-Dose Bolus Fluorouracil Plus Leucovorin and Irinotecan or Infused Fluorouracil Plus Leucovorin and Oxaliplatin in Patients With Previously Untreated Metastatic Colorectal Cancer: A North American Intergroup Trial

    Richard M. Goldberg;Daniel J. Sargent;Roscoe F. Morton;Charles S. Fuchs

Frequent Co-Authors

Richard M. Goldberg
Richard M. Goldberg West Virginia University
Thomas C. Smyrk
Thomas C. Smyrk Mayo Clinic
Axel Grothey
Axel Grothey University of Tennessee at Knoxville
Jeff A. Sloan
Jeff A. Sloan Mayo Clinic
Thierry André
Thierry André Université Paris Cité
Shaker R. Dakhil
Shaker R. Dakhil University of Kansas

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine as a career opens doors beyond the traditional MD route. Many students are choosing online programs to specialize in in-demand healthcare fields. For those interested in pharmacy, understanding online pharmacy school cost is essential, as tuition and program requirements can vary widely.

Health Information Management (HIM) is a rapidly growing area, integrating technology and patient care. Accredited him programs teach data analytics, medical law, and patient privacy fundamentals, often with flexible online options.

Another pathway is medical billing and coding. This field is accessible through online medical billing and coding courses, which prepare students to handle crucial administrative tasks for clinics and hospitals.

Nursing also offers online advanced degree opportunities. Many prospective nurse practitioners seek the cheapest np school to reduce student debt while gaining valuable clinical expertise.

Each of these options offers a unique path into healthcare, emphasizing affordability, flexibility, and career potential.

Best Scientists Citing Steven R. Alberts

Trending Scientists

Recently Published Articles